tazarotene has been researched along with fluorouracil in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Jiaravuthisan, MM; Muhn, CY; Murphy, F; Sasseville, D; Vender, RB | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM | 1 |
| Jacobs, AA; McClung, A; Modi, G; Orengo, IF; Rosen, T | 1 |
| Anolik, R; Brightman, L; Geronemus, R; Warycha, M | 1 |
2 review(s) available for tazarotene and fluorouracil
| Article | Year |
|---|---|
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; Fluorouracil; Humans; Injections, Intralesional; Nail Diseases; Nails; Nicotinic Acids; Photochemotherapy; Phototherapy; Psoriasis | 2007 |
Do lasers or topicals really work for nonmelanoma skin cancers?
Topics: Administration, Cutaneous; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemexfoliation; Dermatologic Agents; Fluorouracil; Humans; Imiquimod; Laser Therapy; Nicotinic Acids; Paget Disease, Extramammary; Photochemotherapy; Skin Neoplasms | 2011 |
4 other study(ies) available for tazarotene and fluorouracil
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea | 2008 |
Combination therapy with imiquimod, 5-fluorouracil, and tazarotene in the treatment of extensive radiation-induced Bowen's disease of the hands.
Topics: Aminoquinolines; Antineoplastic Agents; Biopsy; Bowen's Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Hand; Humans; Imiquimod; Male; Middle Aged; Neoplasms, Radiation-Induced; Nicotinic Acids; Skin Neoplasms | 2010 |